{"aliases":[{"type":"Synonym","name":"toripalimab"},{"type":"Synonym","name":"anti-PD-1 monoclonal antibody JS001"},{"type":"CodeName","name":"JS001"},{"type":"CASRegistryName","name":"1924598-82-2"},{"type":"CodeName","name":"TAB 001"},{"type":"CodeName","name":"TAB-001"},{"type":"ForeignBrandName","name":"Tuoyi"},{"type":"USBrandName","name":"Loqtorzi"}],"definition":{"html":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","text":"A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/toripalimab-tpzi","text":"Toripalimab-tpzi"},"nciConceptId":"C131334","nciConceptName":"Toripalimab","termId":785704,"name":"toripalimab-tpzi","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"toripalimab"}